R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b […]
